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treatment. In type 2 diabetic patients, 35 % stopped insulin glargine and 38 % insulin 
detemir. In only 15% of the patients discontinuing the initiated basal insulin, death 
or switch to other insulin or GLP-1RA explained the discontinuation suggesting non-
adherence to insulin therapy from other reasons. ConClusions: There is a consider-
able proportion of diabetic patients discontinuing their initiated basal insulin analog. 
Future studies are warranted to examine the detailed reasons for discontinuation.
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objeCtives: Patient perceived barriers to intensifying treatment may lead to sub-
optimal glycaemic control. This study assessed patient experience with insulin in 
Germany, preferences on insulin injection, and behaviours associated with inten-
sification in insulin-treated type 2 diabetes mellitus (T2DM) patients. Methods: 
Adults with T2DM diagnosed > 6 months ago and receiving insulin for ≥ 3 months 
were recruited through a representative online panel in Germany. Data were col-
lected via an online questionnaire. Results: Of the 302 respondents, mean age 
was 56 years, with average 12 years since diagnosis and 7 years on insulin. Only 
82% (247/302) knew their HbA1c with 37% (111/302) reporting HbA1c> 8.0%. Overall, 
87% (263/302) had BMI≥ 25kg/m2, with 56% (169/302) BMI≥ 30. Basal-only insulin was 
used by 32% (96/302), short-acting (bolus) insulin only 13% (38/302), basal-bolus 47% 
(142/302), premix 7% (22/302). A total of 72% (216/302) reported ever having a non-
severe (self-managed) hypoglycaemic event with 19% (42/216) of these reporting 
events occurring once-a-week or more. Also, 19% (57/302) reported at some point 
having a severe (requiring help to manage) hypoglycaemic event. 67% (201/302) 
respondents tested blood glucose 3-6 times daily. 12% (11/96) of the basal-only 
respondents had previously received basal-bolus but returned to long-acting insulin 
due to various issues. A total of 51% (49/96) currently on basal-only would hesitate 
to some degree if asked by their physician about intensifying treatment (switch to 
basal-bolus or premix). Most frequent reason was number of daily injections (39%, 
19/49), followed by dose calculation and timing (37%, both 18/49), risk of hypoglycae-
mia (35%, 17/49) and weight gain (33%, 16/49). ConClusions: Number and timing 
of injections, dose calculation, risk of hypoglycaemia and weight gain may present 
barriers to insulin intensification among T2DM patients on basal insulin in Germany, 
and contribute to suboptimal HbA1c control. Therapies addressing these challenges 
may help to achieve treatment goals.
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objeCtives: Factors other than efficacy and safety may influence choice 
of treatment for the patient. Barriers to intensification may lead to poor 
glycaemic control. This study aimed to assess patient barriers and behaviours 
relating to intensification of treatment in insulin-treated Type-2-diabetes (T2DM) 
in the Netherlands. Methods: Patients diagnosed > 6 months ago and receiving 
insulin for ≥ 3 months were recruited through a representative online panel in 
the Netherlands. Data were collected using a web-based questionnaire. Results: 
The 315 respondents had mean age of 59 years, BMI 31kg/m2 and 8-years insulin 
treatment. Of the 179 who knew their HbA1c, 45 (25.1%) were uncontrolled (> 8%) 
with mean HbA1c 9.7%. Overall, basal-only insulin was used by 31.1% (98/315), 
with 6.7% (21/315) on short-acting only (bolus), 47.9% (151/315) basal-bolus, 11.8% 
(37/315) premix and 2.5% (8/315) other. Of the respondents whose main contact 
was primary care, only 17.2% (10/58) of basal-only patients reported ever attend-
ing secondary care for treatment, compared with 32.3% (20/62) on basal-bolus. 
Compared to those on basal-only, more respondents on basal-bolus stated they 
sometimes forget to take insulin (17.3% (17/98) vs 31.1% (47/151), respectively) 
or were likely to forget to pack insulin when travelling or leaving home (6.1% 
(6/98) vs 17.9% (27/151)). If asked by their physician, 41% of basal-only patients 
would hesitate to intensify treatment through adding bolus/switching to premix. 
Most frequent reason was increased number of daily injections (45.0%, 18/40), as 
well as difficulty calculating mealtime dose and risk of weight gain (both 40.0%; 
16/40), timing of dosing with meals (37.5%; 15/40) and hypoglycaemia risk (30.0%; 
12/40). ConClusions: Patients on intensified regimens may require increase 
used of secondary care, whilst number/timing of injections, dose calculation, 
hypoglycaemia risk and weight gain are barriers to insulin intensification among 
T2DM patients on basal insulin. Therapies addressing these may help to achieve 
treatment goals.
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objeCtives: The progressive nature of Type-2 diabetes mellitus (T2DM) requires 
periodic intensification of therapy. Understanding the potential barriers to this 
from patients will support appropriate treatment selection. This study aimed to 
assess hypoglycaemic events, treatment convenience and potential barriers to treat-
ment intensification in Italy. Methods: A web-based survey of subjects with type 
2 diabetes, diagnosed > 6 months previously and receiving insulin for ≥ 3 months, 
recruited via a representative online panel. Results: 302 patients were recruited. 
Mean body mass index (BMI) was 27 kg/m2, with 24% (72/302) BMI> 30kg/m2. Of the 
218 reporting exact HbA1c, 75 (34%) had HbA1c> 8.0%. Of the 72 with BMI> 30kg/m2 
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objeCtives: Studies indicate that poor adherence and low persistence to treat-
ment could lead in not achieving recommended glycemic goals in T2DM patients. 
The aim of this study was to assess the adherence and persistence of patients 
who initiate treatment with insulin or with glucagon-like peptides analogs (GLP-
1) in Spain. Methods: Observational, retrospective study based (funded by GSK) 
on review of medical records from patients located in Badalona sanitary area (1 
hospital and 6 primary care centers). Inclusion criteria: patients ≥ 20 years old 
who initiated treatment with insulin or GLP-1 during 2010-2012, T2DM diagnosis 
at least one year before initiation of injectable treatment. Patients were followed 
for one year. Adherence and persistence during the follow up period were ana-
lyzed. Medication Possession Ratio (MPR) was used as a proxy of adherence. MPR 
is calculated as the percentage of days covered by the medication prescribed 
during the study period. Persistence rate is defined as percentage of patients 
having prescriptions of the ongoing therapy continuously renewed without a gap 
of more than 30 days. Results: 1,301 patients were recruited, mean age was 67.6 
years, 51.6% men, 935 initiated with insulin and 366 with GLP-1. In comparison 
with insulin, patients treated with GLP-1 showed higher adherence to treatment 
(88.1% vs 82.7%; p< 0.001). Higher persistence is also achieved with GLP-1 vs insu-
lin (62.0% vs 55.9%; p= 0.046). After 3 months treatment persistence rate start 
to diverge and differences are maintained during the study period (6 months, 
persistence rate 86.1% for GLP-1 vs 79.4% for insulin; 10 months 77.1% vs 70.8%, 
respectively) ConClusions: Adherence and persistence to treatment seems to 
be higher with GLP-1 than insulin in T2DM patients in Spain. Further studies are 
needed to identify reasons for those differences between treatments. The overall 
management of T2DM should address adherence and persistence as key drivers 
for achieving therapeutic goals.
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objeCtives: Medication adherence and satisfaction with treatment are key 
dimensions of healthcare quality. Large proportion of patients with type 2 dia-
betes mellitus (T2DM) receive oral combination therapy. We aimed to assess 
medication adherence and treatment satisfaction in T2DM patients receiving 
oral combination therapy in a real-world setting. Methods: 160 T2DM patients 
receiving combination therapy for at least 6 months (mean 6.5 yrs, 0.6–17 yrs) 
were enrolled in the multicenter real-world study: cohort 1 – vildagliptin plus 
metformin (mean age 59.6 yrs; male/female 25/57); cohort 2 – sulfonylurea (SU) 
plus metformin (mean age 65.1 yrs; male/female 23/55). All the patients com-
pleted the Morisky Medication Adherence Scale (MMAS 4) and the checklist for 
assessment of treatment satisfaction. Statistical analysis was made using t-test 
and χ 2 criterion. Results: As a whole, 90% patients had good adherence with 
treatment; 50% in cohort 1 vs 36% in cohort 2 were completely adhered with 
medication. Treatment satisfaction was high-rated by the patients; there were no 
patients who were extremely dissatisfied with treatment. All aspects of treatment 
satisfaction – overall treatment satisfaction (0.82 vs 0.54), treatment efficacy (0.98 
vs 0.58), treatment convenience (0.8 vs 0.54) and coping with hypoglycemia (1.06 
vs 0.63) were significantly lower in cohort 2 as compared to cohort 1 (p< 0.02). In 
addition, 59% patients in cohort 2 experienced hypoglycemia vs 28% from those 
in cohort 1. The proportion of patients with better coping with hypoglycemia was 
higher in cohort 1 than in cohort 2 (53.7% vs 31.2; p< 0.006). ConClusions: In 
general, good levels of medication adherence and treatment satisfaction in T2DM 
patients receiving oral combination therapy were demonstrated in a real-world 
setting. Combination of vildagliptin plus metformin was more preferable from 
patients’ perspective in terms of medication adherence and treatment satisfaction 
as compared to SU plus metformin.
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objeCtives: Poor medication adherence is common in diabetes potentially causing 
poor health outcomes and complications. The aim of this study was to analyze the 
discontinuation rate of initiated basal insulin analog in type 1 and type 2 diabetic 
patients in Finland. Methods: The data was obtained from the national reimburse-
ment registry. Study population consisted of 14 462 diabetic patients (18% had type 
1 diabetes) who started basal insulin analogs (insulin glargine or insulin detemir) in 
2012. Patients were followed by their insulin purchases for 18 months after the ini-
tiation. The data was analysed with χ 2-test and logistic regression analysis. Logistic 
regression analysis was used to find out what variables (age, gender, type of diabetes, 
type of insulin analog) explain patient staying in the treatment. Results: Type of 
insulin, gender, age and type of diabetes had statistically significant influence on 
patients’ treatment adherence (p < 0.001 for all). Overall 47 % of patients starting 
insulin detemir and 39 % starting insulin glargine patients discontinued their basal 
insulin treatment within 18 months of the initiation. Most of the patients stopped 
treatment within first 6 months after the initiation. In type 1 diabetic patients, 42 % 
of insulin glargine patients and 57 % of insulin detemir patients stopped the initiated 
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USA
objeCtives: Diabetes Mellitus is best managed through a combination of HbA1c 
testing, self-testing of blood glucose, and close interactions with HCPs. It has been 
previously shown that Italian diabetes patients have a very low rate of adherence 
to appropriate care, compared to those in other EU countries. In this study, we 
examined Italian diabetes patient preferences related to education and moni-
toring compared to patients in other EU5 countries. Methods: A total of 3,013 
diabetes patients in the EU5 were sampled. Questions focused on demographic, 
lifestyle, treatment, access to information, and socioeconomic status. Data were 
compared across countries and reported behaviors compared to current patient 
treatment guidelines. Results: Despite guidelines stating that all patients must 
receive HbA1c testing twice per year, 42.5% of Italian patients reported receiving 
an HbA1c test in the past 12 months compared to 70.5% in other EU5 countries. 
Instead, these patients are favoring blood glucose self-monitoring, which has 
been previously shown to be an insufficient substitute for HbA1c testing. Italian 
patients also claimed that they do not want their doctor or nurse managing their 
diabetes more so than patients in any other tested country. Italians get diabetes 
information from Newspapers/Magazines, Internet, TV/Radio, Relatives/Friends 
more than other Europeans (37% v 34%; 33% v 28%; 30% v 26%; 25% v 21% respec-
tively). ConClusions: While many Italian diabetes patients are reporting low 
adherence to guideline driven testing and preferences for managing their own 
diabetes without intervention from their HCP, change is needed. This represents a 
major opportunity for more targeted Italian patient management solutions built on 
Italian patient preferences and recognition of necessary change drivers to realize 
more cost-effective care. This study demonstrates how local patient preferences can 
impact outcomes, and therefore must be built into chronic disease management 
solutions for meaningful change to occur.
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objeCtives: Type 1 diabetes is often associated with complications that may have 
a pronounced impact on health-related quality of life (HRQoL). The aim was to 
conduct a systematic literature review to identify studies conducted exclusively in 
type 1 diabetes populations reporting utility values for diabetes-related complica-
tions. Methods: Literature searches of the PubMed, EMBASE and Cochrane Library 
databases were performed in line with PRISMA guidance; searches used Medical 
Subject Heading (MeSH) terms supplemented with free-text terms. For inclusion, 
studies were required to be conducted exclusively in adults with type 1 diabe-
tes, published in English from 2000 onwards, and report utility values determined 
using either direct or indirect assessment methods. Results: Searches identified 
a total of 20 studies reporting utility values for complications in type 1 diabetes, 
of which a total of 9 studies used the EQ-5D, 2 used the 15D, 3 used the Quality of 
Well-Being questionnaire and 5 used direct methods including time trade-off and 
standard gamble. For patients with no complications reported utility values ranged 
from 0.90–0.98. Complications including stroke (reported disutility range −0.105 to 
−0.291), neuropathy (range −0.055 to −0.358) and blindness (range −0.132 to −0.208) 
were associated with among the largest decrements in utility values. Poor glycemic 
control was also found to be associated with lower utility values. Data gaps in the 
literature exist, e.g. EQ-5D utility values for amputation and end-stage renal dis-
ease are lacking. ConClusions: Differences between type 1 and type 2 diabetes 
populations mean for economic evaluation it is preferable to obtain utility values 
from exclusively type 1 diabetes populations. In type 1 diabetes the presence of 
complications has a significant detrimental impact on HRQoL, but the magnitude of 
the impact depends on the choice of HRQoL instrument. This will have implications 
on cost-effectiveness models of type 1 diabetes.
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objeCtives: Diabetes mellitus (DM) is a chronic disease and patients have higher 
objective healthcare needs compared to the general population. The healthcare sup-
portive services help the good control of diabetes, avoiding or delaying the disease 
complications and assuring the patient’s adherence to the treatment. The objec-
tive of this study is to assess the patients reported needs of additional healthcare, 
psychological or family supportive care and the specific gaps in the healthcare 
management of the disease in Bulgaria. Methods: A total of 245 adults diagnosed 
with DM type 1 and 2 were recruited and completed a self-report questionnaires at 
three hospitals - in the capital and in two main other cities. Of them 203 were com-
plete and eligible for analysis. Unmet needs were assessed using 15-item question-
naire. The data were examined using descriptive statistics. Results: Unmet needs 
were most commonly reported in the aspects of healthcare services’ domains. The 
three most frequently endorsed items of “moderate to severe” unmet needs were: 
additional information about the disease from the endocrinologist (65.35%), struc-
tured information about the disease and its treatment given in the hospital from 
the doctor (68.81%) and needs of special foot care medical offices for patients with 
diabetic neuropathy (68.81%). Approximately 76% of the patients reported having 
unmet needs of more free test-strips for self-monitoring blood glucose, medicinal 
products and special healthcare services for diabetics. 73 patients (36.14%) reported 
high importance of the active participation of the pharmacist in community phar-
macy in recognizing of probable and current drug related problems. 101 of the 
patients (50%) reported need of higher psychological support from their relatives 
18 had HbA1c> 8.0%. A total of 42% (126/302) used basal-insulin only, 29% (88/302) 
bolus-insulin only, 22% (66/302) basal-bolus, 5% (16/302) premixed and 2% (6/302) 
other combinations. Of all respondents, 81% (246/302) had previously experienced 
non-severe (self-managed) hypoglycaemia (79% (59/75) in those with HbA1c> 8%), 
with 11% (28/246) reporting 3 events per-week, 33% (80/246) once-a-week, and 29% 
(72/246) once-a-month. 30% (92/302) had previously experienced severe hypoglycae-
mia requiring help from others, with half (46/92) reporting 1-3 such events during 
past year. 73% (221/302) of respondents tested blood glucose 2-5 times-daily. Of 
192 respondents using basal insulin, 134 (70%) injected ≤ 1 time-a-day, whilst 30% 
(58/192) injected ≥ 2 times-daily. When asked about intensifying by adding bolus-
insulin or switching to premix, 58% (73/126) of basal-only patients would be hesitant. 
Most frequent reason for hesitation was increased number of daily injections (44%, 
32/73), as well as pain/discomfort of injections and risk of weight gain (both 23%; 
17/73), hypoglycaemia risk (22%; 16/73), difficulty calculating bolus dose with food 
(21%; 15/73). ConClusions: Number and timing of injections, dose calculation, 
risk of hypoglycaemia and weight gain are barriers to insulin intensification among 
T2DM patients on basal insulin in Italy. Therapies addressing these may help to 
achieve treatment goals.
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objeCtives: Diabetes mellitus is a serious health problem. Medication adherence 
is a key determinant of therapeutic success in patients with diabetes mellitus. 
The purpose of this study was to assess medication adherence and its potential 
association with diabetes related knowledge in patients with type 2 diabetes mel-
litus. Methods: This study was carried out at the outpatient clinics of a public 
sector teaching hospital in Sargodha, Pakistan. Besides demographic and dis-
ease-related questions, previously validated questionnaires, Morisky Medication 
Adherence Scale and Michigan diabetes knowledge test was used to assess the 
medication adherence and diabetes related knowledge, respectively. Descriptive 
statistics were used to determine the demographic and disease characteristics 
of the patients while Spearman rank correlation was employed to measure the 
association between medication adherence and knowledge. Results: Three hun-
dred and ninety two patients were interviewed. Out of 392 patients, 245 (62.5%) 
of the patients had average knowledge about diabetes while 282 (71.9 %) were 
categorized as poor adherent. Only 13 patients (3.3 %) were considered as good 
adherent in the study. The correlation coefficient between total scores of knowl-
edge and total medication adherence score was 0.036 (p< 0.05), indicating a weak 
correlation between knowledge scores and adherence level. ConClusions: 
Knowledge of diabetes mellitus among these patients was average; however, 
adherence to drug therapy was also poor. Patients’ knowledge about diabetes had 
positive association with medication adherence. Improving diabetes knowledge 
of people can result in better adherence, which may result in better control of 
diabetes.
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objeCtives: Patient adherence with a therapeutic regimen predicts success-
ful treatment and reduces the severity of negative complications. The objective 
of this study was to explore the relationship between Health-Related Quality of 
Life (HRQoL) and treatment adherence among type 2 diabetes mellitus patients 
in Sargodha, Pakistan. Methods: The study was designed as a cross-sectional 
descriptive survey. Type 2 diabetic patients attending a tertiary care institute in 
Sargodha, Pakistan were targeted for the study. The Urdu version of the Morisky 
Medication Adherence Scale (MMAS-Urdu) and EuroQol Quality of Life Scale (EQ-
5D) was used to assess medication adherence and HRQoL, respectively. Descriptive 
statistics were used for the elaboration of socio-demographic characteristics. The 
Spearman’s Rho correlation test was used to measure the association between 
medication adherence and HRQoL. P < 0.05 was taken as significant. Results: 
Three hundred and ninety two patients were approached for the study. The cohort 
was dominated by males (n= 222, 56.60 %) with 5.58± 4.09 years of history of type 2 
diabetes mellitus. The majority of respondents (n= 137, 34.90 %) was categorized in 
age group of 51 to 60 years with mean age of 50.77 ± 9.671 years. The present study 
highlighted that individuals with type 2 diabetes mellitus had decreased HRQoL 
(0.4715 ± 0.3360) and poor medication adherence (4.44± 1.8). Significant, yet weak 
positive correlations were observed between medication adherence and HRQoL (r= 
0.217 and 0.136 for EQ-5D and EQ-VAS respectively). ConClusions: Although the 
association between adherence to therapeutic regimen and HRQoL in the present 
study cohort was significant, it was rated as weak, hence failed in producing an 
overall impression on quality of life. The study, therefore, highlights the need to 
identify other individual factors affecting HRQoL among type 2 diabetes mellitus 
patients in Pakistan.
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